Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Articulinx Inc.

This article was originally published in Start Up

Executive Summary

Osteoarthritis affects almost 21 million Americans aged 25 or older, and is most prevalent in the hand. The need for an alternative to long-term drug therapy for treating early stage hand OA is a vastly underserved market that Silicon Valley-based Articulinx Inc. hopes to address with its Intercarpometacarpal Cushion, a spacer device used to augment cartilage in the basal joint of the thumb.

You may also be interested in...

Orthox Ltd.

UK-based Orthox Ltd. has developed a meniscus replacement technology derived from the high-strength silk proteins found in spider web. The company is hoping to offer the best long-term, load-bearing solution for this underserved segment of the orthopedics market.

Carticept Medical Inc.

Carticept Medical Inc. is working to become the first company with a synthetic cartilage replacement device for use in the earlier stages of knee OA that allows immediate weight bearing, with future applications in the hand and foot. The company also is awaiting 510(k) clearance for its Navigator all-in-one orthopedic injection system combined with ultrasound guidance.

Cartilage Repair: Opportunities In Motion-Preserving Orthopedics

Start-ups and investors are looking to address the large and growing gap between palliative treatment and major joint surgery for patients with cartilage damage in the knee, toes and hands - although the FDA is putting up more roadblocks than ever before. In this issue we profile Articulinx, Carticept Medical and Orthox.

Related Content

Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts